# A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

> **NCT00964704** · PHASE2 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** capecitabine [Xeloda]
- **DRUG:** docetaxel
- **DRUG:** trastuzumab [Herceptin]

## Key facts

- **NCT ID:** NCT00964704
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients have been recruited therefore study has been cancelled
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00964704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00964704, "A Study of Herceptin (Trastuzumab) in Combination With Avastin (Bevacizumab) and Sequential Xeloda (Capecitabine) or Docetaxel in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00964704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*